Detailed Narrative
ENHANZE Platform Performance and Diversification
Halozyme's ENHANZE platform continues to demonstrate repeatability, scalability, and durability, driving record royalty revenue growth. The company has successfully diversified its royalty streams from a focus on DARZALEX SC to now include PHESGO, VYVGART Hytrulo, and newer launches like OPDIVO SC, OCREVUS SC, and RYBREVANT SC, which collectively grew 80% quarter-on-quarter. This broadened portfolio resulted in a 50% year-over-year increase in total royalty revenue to $308 million, supporting long-term financial guidance.
Hypercon as a Second Compounding Engine
Hypercon is emerging as a second platform engine, designed for lower volume subcutaneous administration and highly concentrated formulations. The company is advancing preparations for the first Hypercon clinical starts in H1 2027, with projected first product launches in 2030-2031. Halozyme expects Hypercon to achieve approximately $1 billion in royalty revenue by the mid-2030s, with 5 to 7 launches contributing to this target, potentially from both existing and future agreements.
Record New Collaboration Agreements
Halozyme signed 4 new collaboration and licensing agreements in Q2 and a fifth in July, marking its most successful year for new deals. These include three new ENHANZE agreements (with GSK, Incyte, and an undisclosed partner) and two new Hypercon agreements (with Vertex and Oruka). Notably, ENHANZE expanded into new modality areas: Antibody Drug Conjugates (ADCs) and nucleic acids, representing new growth segments with an estimated 100 commercial and development products that could benefit. These new CLAs contributed $35.5 million in upfront collaboration revenue.
Pipeline Expansion and Future Royalty Streams
The company is actively expanding its pipeline of future royalty streams, with 2 new ENHANZE targets initiating Phase I testing in Q2, bringing the total to 9 development programs. Halozyme aims to have 13 ENHANZE development programs by year-end 2026, with potential approvals beginning in the 2029+ timeframe. This growing portfolio of future launches is expected to extend revenue opportunities well into the next decade, layering on top of currently approved products.
Capital Allocation and M&A Strategy
Halozyme maintains a disciplined capital allocation strategy focused on funding high-return organic opportunities, maintaining a strong balance sheet, and returning excess capital through share repurchases. The company bought back $332.8 million worth of shares in Q2, targeting $400 million for the full year. While M&A is considered an important part of the strategy for adding differentiated technologies, the focus for 2026 remains on organic growth, with M&A being unlikely this year due to the strong internal portfolio and growing cash flows.
Merck Litigation Update
Halozyme is actively pursuing injunctions in 8 countries outside the U.S. against Merck for infringing use of its technology, with important decisions expected in Europe before year-end. In the U.S., the company is appealing initial PTAB decisions on PGRs and awaiting clarity on the remaining 10 PTAB decisions this fall, which will inform the timing of📎 the U.S. District Court case. Halozyme expresses unwavering confidence in prevailing, citing the infringing nature of Merck's product.
Competitive Landscape and Moat
Management views Alteogen as not directly competing, as companies signing deals with Alteogen often target areas where Halozyme has exclusive licenses. Halozyme emphasizes its competitive moat, built on a track record of success, a large safety database (1.3 million patients, 15 years), reliability of supply, and expertise in supporting rapid clinical advancement and innovative trial designs, which continues to attract new partners.